ORION CORPORATION STOCK EXCHANGE RELEASE 24 MARCH 2015 3.30 p.m.
EET
Orion Corporation: Decisions by the AGM on 24 March 2015
At the Annual General Meeting of Orion Corporation held today, the following
decisions were made:
* A dividend of EUR 1.30 per share was confirmed to be paid for 2014. The
record date for the dividend payment is 26 March 2015 and the payment date
is 2 April 2015.
* The proposals concerning the election and remuneration of the Board of
Directors and the auditor and the number of the members of the Board of
Directors were approved.
* Sirpa Jalkanen, Eero Karvonen, Timo Maasilta, Mikael Silvennoinen, Hannu
Syrjänen, Heikki Westerlund and Jukka Ylppö were re-elected to the Board of
Directors. Hannu Syrjänen was re-elected as Chairman.
The Annual General Meeting of Orion Corporation was held today in Helsinki. The
following matters were handled at the meeting:
Adoption of the Financial Statements for 1 January - 31 December 2014
The AGM confirmed the Financial Statements of the parent company and the Group
as per 31 December 2014.
Dividend EUR 1.30 per share
The proposed dividend of EUR 1.30 per share was approved. The record date for
the dividend payment is 26 March 2015 and the payment date is 2 April 2015.
Discharge from liability
The members of the Board of Directors and the President and CEO were discharged
from liability for the financial period of 1 January - 31 December 2014.
Remunerations to be paid to the Board of Directors
As an annual fee for the term of office of the Board of Directors, the Chairman
shall receive
EUR 76,000, the Vice Chairman shall receive EUR 51,000 and the other members
shall receive EUR 38,000 each. As a fee for each meeting attended, the Chairman
shall receive EUR 1,200, the Vice Chairman shall receive EUR 900 and the other
members shall receive EUR 600 each. The travel expenses of all Board members
shall be paid in accordance with previously adopted practice. The afore-
mentioned fees for each committee meeting attended shall also be paid to the
Chairmen and to the members of the committees established by the Board.
Of the annual fee, 60% shall be paid in cash and 40% in Orion Corporation B-
shares, which shall be acquired to the members during 30 March - 2 April 2015
from the stock exchange in amounts corresponding to EUR 30,400 for the Chairman,
EUR 20,400 for the Vice Chairman and EUR 15,200 for each of the other members.
The part of the annual fee that is to be paid in cash corresponds to the
approximate sum necessary for the payment of the income taxes on the fees and
shall be paid no later than 30 April 2015. The annual fees encompass the full
term of office of the Board of Directors.
Composition of the Board of Directors
Hannu Syrjänen re-elected as Chairman
The number of members in the Board of Directors was confirmed to be seven. Sirpa
Jalkanen, Eero Karvonen, Timo Maasilta, Mikael Silvennoinen, Hannu Syrjänen,
Heikki Westerlund and Jukka Ylppö were re-elected to the Board of Directors for
the next term of office. Hannu Syrjänen was re-elected as Chairman.
Auditor and their remuneration
PricewaterhouseCoopers Oy, authorised public accountants, were re-elected as the
Company's auditor. The remunerations to the Auditor shall be paid on the basis
of invoicing approved by the Company.
The minutes of the AGM will be provided in Finnish only, and they will become
available on Orion's website, http://www.orion.fi/agm2015, no later than 7 April
2015.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO Senior Vice President, Corporate
Functions
Contact person:
Olli Huotari, Senior Vice President, Corporate Functions, phone +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02101 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.
[HUG#1905478]